Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 45,506

Document Document Title
WO/2013/139941
The present invention relates in one embodiment to a pharmaceutical combination of a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator and levodopa or a dopamine agonist, and at least one of a dopa decarboxylase in...  
WO/2013/138322
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine a...  
WO/2013/138602
R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.  
WO/2013/137371
A medicine which can decrease an LDL level in blood and comprises, as an active ingredient, a compound represented by general formula (I) (wherein R1 represents a hydrogen atom or a group represented by formula (II) (wherein R3 represent...  
WO/2013/137777
The invention relates to the field of the pharmaceutical industry and medicine. The problem addressed by the present invention is that of producing an effective pharmaceutical composition having neuroprotector, antiamnesic, antioxidan...  
WO/2013/135596
The invention relates to a new use of a known Rho kinase inhibitor, fasudil or a fasudil derivative selected from hydroy-fasudil or dimethylfasudil, in the treatment of amyotrophic lateral sclerosis (ALS).  
WO/2013/138687
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various diso...  
WO/2013/138463
Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a mo...  
WO/2013/138456
Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a LI...  
WO/2013/136338
The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral...  
WO/2013/137778
The invention relates to the field of the pharmaceutical industry and medicine, and can be used in the production and use of solid dosage forms having neuroprotector, antiamnesic, antioxidant, antihypoxic and antiischaemic activity. T...  
WO/2013/137479
A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents -O- or -CH2-; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower al...  
WO/2013/133448
Provided is a sustained release oral solid preparation comprising aripiprazole or a salt thereof as an active ingredient described below, and a method for producing the sustained release oral solid preparation. A sustained release oral s...  
WO/2013/133650
The present invention relates to a pharmaceutical composition for preventing, alleviating, or treating diseases associated with the cranial nerves or the spinal nerves, containing a stem cell-conditioned culture medium powder. More speci...  
WO/2013/134085
The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACEl) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in ...  
WO/2013/133647
The present invention relates to a novel liquid composition comprised of piroxicam or its pharmaceutically acceptable salt (a non-steroid anti-inflammatory drug) and hyaluronic acid or its pharmaceutically acceptable salt (used for treat...  
WO/2013/134219
Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders m...  
WO/2013/134036
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2013/134403
The present invention relates to compositions and methods for regulating miRNA function in a population of cells or subject. In particular, the invention relates to regulating miRNA function to treat neurodegenerative conditions associat...  
WO/2013/134766  
WO/2013/132490
The invention provides a method of treating benzodiazepine-resistant status epilepticus in a subject having been exposed to a nerve agent inducing the status epilepticus.  
WO/2013/134228
Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders medi...  
WO/2013/132489
The invention provides particular mono- and dinucleoside 5'-phosphorothioate analogues, more particularly mono- or di- adenosine or uridine 5'-di- or tri- phosphorothioate analogues in which at least one of the bridging oxygen atoms of t...  
WO/2013/134047
Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or ...  
WO/2013/134336
This invention is directed to the treatment of pain by inhibiting adaptor associated kinase 1 (AAK1). Numerous AAK1 inhibitors are disclosed.  
WO/2013/132380
Disclosed is a compound of formula (I) wherein Y, Ring D, m and R1-R4 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as pharmaceutically ac...  
WO/2013/134371
The present invention relates to a compound having the general formula. These compounds specifically block the early formation of toxic protein aggregation, e.g. the formation of Αβ oligomers, in a human or animal body. These compounds...  
WO/2013/133325
[Problem] To provide a compound which has excellent serotonin 5-HT2C receptor activating activity. [Solution] A compound represented by formula (1) or a salt thereof. (In the formula, ring A represents an optionally substituted aromatic ...  
WO/2013/132270
A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R and R6 are each independently (LQ) mY; R4 is H, halogen, optionally substituted aryl or optionally substituted alkyl; and; each X is independe...  
WO/2013/129660
The present invention relates to: an agent that is agonistic to an oxytocin receptor and/or antagonistic to a vasopressin receptor, which comprises, as an active ingredient, a peptide represented by general formula (1) Cys-X1-X2-X3-X4-(X...  
WO/2013/129772
The present invention relates to a pharmaceutical composition and food composition comprising Nelumbo nucifera seed extract as an active ingredient for the protection of brain nerve cells. Particularly, the composition is characterized b...  
WO/2013/128276
Disclosed is an immediate release solid oral dosage form comprising (i) an active agent; and (ii) a material that is sensitive to acidic pH;  
WO/2013/129931
The invention relates to a composition comprising: (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), ...  
WO/2013/129413
[Problem] The objective of the present invention is, in a kit that is for preparing a carbon-dioxide-containing composition containing an oxygen-containing gel composition and a carbonate-containing gel composition, to provide a formulat...  
WO/2013/129220
The present invention provides a pharmaceutical, pharmaceutical composition, or food in which a dipeptide comprising Met (M) or an analog thereof and His (H) or an analog thereof is an active ingredient, as well as a method and use for p...  
WO/2013/129977
The invention relates to the field of the pharmaceutical industry and medicine. The problem of the invention consists in producing a pharmaceutical composition having neuroprotector, antiamnaesic, antioxidant, antihypoxic and antiischaem...  
WO/2013/128239
The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss ...  
WO/2013/127728
The present invention relates to a hormone containing oil-in-water emulsion for parenteral administration comprising a) progestogen and/or estrogen and b) fish oil triglycerides, wherein the fish oil triglyceride consists of glycerol whi...  
WO/2013/130826
The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals...  
WO/2013/129443
Provided are: a novel compound having an excellent Aurora-A-selective inhibitory activity and useful as an anti-cancer agent that can be administered orally; a novel anti-tumor effect enhancer for a microtube agonist comprising a taxane-...  
WO/2013/127727
The invention relates to hormone containing oil-in-water emulsion for parenteral administration comprising progestogen and/or estrogen; a phospholipid comprising one or two omega-3 fatty acid moieties; and an oil as well as a pharmaceuti...  
WO/2013/126963
This invention is directed to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA ...  
WO/2013/127913
The invention, in a first aspect relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 6-membered aromatic ring, or a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected...  
WO/2013/128086
The present invention relates to a novel pharmaceutical composition which is in syrup form. This novel composition comprises: modafinil, in the form of its S enantiomer, - excipients, sugar, purified water. Use of the pharmaceutical comp...  
WO/2013/130577
Pharmaceutical compositions for the treatment of nasal congestion or migraine, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective α-2 adrenergic receptor agonists.  
WO/2013/127918
The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and relate...  
WO/2013/130402
Disclosed is a hemisulfate salt of Compound (I): and crystalline forms of the hemisulfate salt. Also disclosed are methods of using the hemisulfate salt of Compound (I) as a CGRP receptor antagonist, and pharmaceutical compositions compr...  
WO/2013/130890
Heterobicyclic compounds of Formula (I): (I); or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provid...  
WO/2013/129622
The present invention provides a compound having cholinergic muscarinic M1 receptor positive allosteric modulator activity, that is useful as a drug for preventing or treating Alzheimer's disease, schizophrenia, pain, sleep disorders, an...  
WO/2013/130150
Methods and compositions for treating a subject suffering from exposure to a chemical threat agent are disclosed.  

Matches 651 - 700 out of 45,506